Table 2. FDA approved drug recommendations listed by mutation and source.
| Gene | Foundation | DGIdb | MCG | PCT | cBioPortal |
|---|---|---|---|---|---|
| AKT1 | Everolimus, Temsirolimus | Everolimus, Temsirolimus, Nelfinavir, Risperidone | Everolimus, Temsirolimus, Metformin, Sirolimus | Arsenic Trioxide | |
| AKT2 | Everolimus, Temsirolimus | Everolimus | |||
| AKT3 | Everolimus, Temsirolimus | Everolimus | |||
| ATR | Olaparib | ||||
| BRAF | Sorafenib, Trametinib, Regorafenib | Sorafenib, Dabrafenib, Vemurafenib, Regorafenib, Trametinib, Dasatinib, Temsirolimus | Dabrafenib, Vemurafenib, Trametinib | Sorafenib, Dabrafenib, Vemurafenib, Regorafenib, Trametinib | Sorafenib, Dabrafenib, Vemurafenib |
| BTK | Ibrutinib | Ibrutinib | Ibrutinib | ||
| CCND1 | Arsenic Trioxide, Methotrexate | Arsenic Trioxide | |||
| CTNNB1 | Celecoxib | ||||
| EGFR | Afatinib, Erlotinib, Gefitinib, Cetuximab, Lapatinib, Panitumumab | Afatinib, Erlotinib, Gefitinib, Cetuximab, Lapatinib, Panitumumab, Vandetanib, Lidocaine, Trastuzumab, Bevacizumab, Pazopanib, Pertuzumab | Afatinib, Erlotinib, Gefitinib, Vandetanib | Afatinib, Erlotinib, Gefitinib, Cetuximab, Lapatinib, Panitumumab, Vandetanib, Lidocaine, Trastuzumab | |
| ERBB2 | Afatinib, Lapatinib, Pertuzumab, Trastuzumab, Ado-trastuzumab | Afatinib, Lapatinib, Pertuzumab, Trastuzumab, Ado-Trastuzumab, Bevacizumab, Gefitinib | Afatinib, Lapatinib | Afatinib, Lapatinib, Pertuzumab, Trastuzumab | |
| ERBB3 | Afatinib, Pertuzumab | Gefitinib | |||
| ESR1 | Clomiphene, Danazol, Desogestrel, Estramustine, Estropipate, Ethinyl Estradiol, Ethynodiol Diacetate, Fluoxymesterone, Fulvestrant, Levonorgestrel, Medroxyprogesterone, Megestrol, Naloxone, Norgestimate, Norgestrel, Progesterone, Raloxifene, Tamoxifen, Toremifene, Anastrozole, Cisplatin, Exemestane, Leflunomide, Letrozole | Clomiphene, Danazol, Desogestrel, Estramustine, Estropipate, Ethinyl Estradiol Ethynodiol Diacetate, Fluoxymesterone, Fulvestrant, Levonorgestrel, Medroxyprogesterone, Megestrol, Naloxone, Norgestimate, Norgestrel, Progesterone, Raloxifene, Tamoxifen, Toremifene, Bazedoxifene | |||
| FGF4 | Pentosan Polysulfate | Pentosan Polysulfate | |||
| FGFR1 | Regorafenib, Ponatinib, Pazopanib | Regorafenib, Ponatinib, Palifermin | Ponatinib, Nintedanib | Regorafenib, Ponatinib, Pazopanib, Dasatinib, Sorafenib, Sunitinib, Vandetanib | Regorafenib, Palifermin |
| FGFR2 | Ponatinib, Pazopanib | Ponatinib, Palifermin, Regorafenib, Thalidomide, Interferon, Pentosan Polysulfate | Ponatinib, Nintedanib | Ponatinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib | Palifermin, Thalidomide |
| FGFR4 | Ponatinib | Palifermin | Palifermin | ||
| FLT3 | Sorafenib, Sunitinib, Ponatinib | Sorafenib, Sunitinib, Ponatinib, Cabozantinib, Azacitidine, Bortezomib, Clofarabine, Idarubicin | Sorafenib, Sunitinib, Ponatinib, Cabozantinib | Sorafenib, Sunitinib, Ponatinib, Cabozantinib, Vandetanib, Pazopanib, Regorafenib | Sorafenib, Sunitinib, Vandetanib |
| FLT4 | Axitinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Vandetanib | Axitinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Vandetanib | Axitinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Vandetanib, Cabozantinib | ||
| GNAS | Trametinib | ||||
| HRAS | Trametinib | ||||
| IGF1R | Glargine Insulin, Lispro Insulin, Porcine Insulin | Glargine Insulin, Lispro Insulin, Porcine Insulin, Mecasermin | |||
| JAK2 | Ruxolitinib | Ruxolitinib | Ruxolitinib | ||
| JUN | Arsenic Trioxide, Irbesartan, Vinblastine | Arsenic Trioxide, Irbesartan, Vinblastine | |||
| KDR | Pazopanib, Sorafenib, Sunitinib, Vandetanib, Axitinib, Regorafenib, Bevacizumab | Pazopanib, Sorafenib, Sunitinib, Vandetanib, Cabozantinib, Ramucirumab, Regorafenib, Ponatinib | Pazopanib, Sorafenib, Sunitinib, Vandetanib, Axitinib, Cabozantinib, Ramucirumab | ||
| KIT | Dasatinib, Imatinib, Pazopanib, Regorafenib, Sunitinib, Nilotinib, Sorafenib, Ponatinib, Everolimus, Temsirolimus | Dasatinib, Imatinib, Pazopanib, Regorafenib, Sunitinib, Axitinib, Nilotinib, Sorafenib, Cabozantinib | Dasatinib, Imatinib, Pazopanib, Regorafenib, Sunitinib, Axitinib, Cabozantinib | Dasatinib, Imatinib, Pazopanib, Regorafenib, Sunitinib, Axitinib, Nilotinib, Sorafenib, Cabozantinib, Pazopanib, Ponatinib | Dasatinib, Imatinib, Pazopanib, Regorafenib, Sunitinib, Axitinib, Nilotinib, Sorafenib, Cabozantinib, Vandetanib |
| KRAS | Trametinib | Trametinib, Cetuximab, Everolimus, Erlotinib, Gefitinib, Panitumumab, Regorafenib, Simvastatin, Temsirolimus, Vandetanib | Trametinib | ||
| MAP2K2 | Trametinib | Trametinib, Dabrafenib | Trametinib | ||
| MAP2K4 | Trametinib, Dabrafenib | ||||
| NF1 | Everolimus, Temsirolimus, Trametinib | Trametinib | |||
| PDGFRB | Imatinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Dasatinib, Everolimus, Ponatinib, Temsirolimus | Imatinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Axitinib, Dasatinib, Nilotinib | Imatinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Axitinib, Nintedanib | Imatinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Axitinib, Dasatinib, Nilotinib, Cabozantinib | |
| PIK3CA | Everolimus, Temsirolimus | Everolimus, Temsirolimus, Docetaxel | Everolimus, Temsirolimus, Sirolimus, Metformin | ||
| PIK3R1 | Everolimus, Temsirolimus | Isoproterenol | Isoproterenol | ||
| PTEN | Everolimus, Temsirolimus | Everolimus, Temsirolimus, Cetuximab, Erlotinib, Gefitinib, Panitumumab, Vandetanib | Everolimus, Temsirolimus, Sirolimus | ||
| RARA | Acitretin, Etretinate, Isotretinoin, Arsenic Trioxide, Tretinoin | Acitretin, Etretinate, Isotretinoin | |||
| RB1 | Porcine Insulin, Recombinant Insulin | Porcine Insulin, Recombinant Insulin | |||
| RPTOR | Everolimus, Temsirolimus | Sirolimus, Temsirolimus | |||
| SRC | Dasatinib, Bosutinib | Dasatinib, Bosutinib, Ponatinib | Dasatinib | Dasatinib, Bosutinib | |
| STK11 | Everolimus, Temsirolimus | ||||
| TET2 | Azacitidine, Decitabine | ||||
| TOP1 | Irinotecan, Topotecan | Irinotecan, Topotecan | Irinotecan, Topotecan | ||
| TP53 | Fluorouracil, Paclitaxel | ||||
| TSC2 | Everolimus, Temsirolimus | ||||
| VHL | Axitinib, Cabozantinib, Everolimus, Pazopanib, Ponatinib, Ramucirumab, Regorafenib, Sorafenib, Temsirolimus, Sunitinib, Vandetanib |
Note: Drugs with overlap in recommendation sources are listed in bold for four-way overlap and in bold + underline for five-way overlap.